Voyager Therapeutics inventory pops 30% on cope with Novartis

Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech within the medical sector that makes a speciality of gene remedy for neurological ailments. Its shares took a 30% spike on information of its partnership with Novartis AG NYSE: NVS. The deal is a collaboration and capsid licensing settlement price as much as $1.3 billion. It additionally validates Voyagers TRACER capsid discovery platform.

Whereas shares spiked to a excessive of $11.72 on Jan. 5, 2024, they shortly fell on Jan. 5, 2024, with the announcement of a secondary providing of widespread inventory costs at $9.00 per share. The prepare has returned to the station for traders trying to board.

Voyager Therapeutics

Whereas not a broadly identified biotech, Voyager focuses on gene remedy growth, which seeks to interchange or repair defective genes in neurological illness sufferers. Its pipeline consists of packages for amyotrophic lateral sclerosis (ALS), Parkinson’s illness, Alzheimer’s illness, and Huntington’s illness. Their lead candidate is VY-TAU01, an anti-tau antibody program for Alzheimer’s illness.

TRACER capsid discovery platform

Voyager developed its proprietary tropism redirection of AAV cell-type-specific expression RNA) TRACER capsid discovery platform. It’s an RNA-based screening platform that may shortly find adeno-associated-virus (AAV) capsids within the mind. TRACER focuses on enhancing the supply of genetic materials to particular areas.

TRACER-generated AAV capsids are like tiny supply vehicles that may carry genetic materials into the mind and central nervous system (CNS) to achieve extremely tough areas. These deliveries are very focused and correct, so they do not find yourself in locations just like the liver or dorsal root ganglia. Voyager has licensed its next-generation TRACER capsids to help its collaboration companions’ gene remedy packages to deal with a lot of ailments.

Novartis is not only GLP-1 medication.

Novartis has been making headlines for its blockbuster GLP-1 weight-loss medication Ozempic and Wegovy, that are taking the world by storm. Nevertheless, Novartis is lively within the gene remedy section and in addition collaborates with Intellia Therapeutics Inc. NASDAQ: NTLA to develop superior CRISPR/Cas 9 gene-editing therapies using CAR-T cells. Take a look at the sector heatmap on MarketBeat.

Novartis $1.3 billion collaboration deal

The partnership with Novartis and Voyager entails growing gene therapies for Huntington’s illness (HD), a hereditary situation the place nerve cells break down over time, and spinal muscular atrophy (SMA), a genetic situation for nerve cells within the spinal twine that controls voluntary muscle actions affecting a toddler’s potential to stroll, crawl and management head actions. Novartis features entry to Voyager’s TRACER capsids to develop gene therapies.

Voyager will lead preclinical growth for HD, and Novartis will deal with medical growth and commercialization and safe world rights to Voyager’s AAV gene remedy for HD.

Monetary particulars of the Novartis partnership

Novartis pays Voyager $100 million upfront, which features a $20 million buy of newly issued Voyager inventory and as much as $1.2 billion in funds for attaining preclinical, growth, regulatory, and gross sales milestones. On Jan. 5, 2023, Voyager priced a $100 million providing of widespread inventory, which included 7.779 million shares priced at $9.00 per share and three.33 million warrants. Get AI-powered insights on MarketBeat.

CEO feedback

Voyager Therapeutics CEO Dr. Alfred Sandrock Jr. commented, “Combining the confirmed capabilities of Novartis in gene remedy growth and commercialization with Voyager’s next-generation TRACER capsids and payloads might allow the development of essential new therapies for sufferers. As well as, the consideration Voyager will obtain from this collaboration will strengthen our steadiness sheet and prolong our runway into mid-2026.”

Novartis, President of Biomedical Analysis, commented, “We imagine Voyager’s TRACER capsids maintain promise for enabling next-generation gene therapies for ailments of the central nervous system, aligning nicely with our deep neuroscience experience and gene remedy management at Novartis.”

Opera analyst rankings and worth targets are at MarketBeat. Opera friends and competitor shares could be discovered with the MarketBeat inventory screener.

 Each day cup sample

The every day candlestick chart for VYGR illustrates a cup sample. The cup lip line shaped at $10.32 on Sept.1, 2023. Shares offered off to a low of $6.06 on Nov. 13, 2023. VYGR staged a rally again up by its 50-period shifting common, stalling at its every day 200-period shifting common (MA) till the discharge of the Novartis deal.

Shares spiked to $11.72 earlier than collapsing again down in the direction of the $9.00 worth degree, which was the $100 million secondary providing’s worth degree. The every day relative power index (RSI) fell sharply from the 80-band by the 60-base in the direction of the 70-band. Pullback help ranges are at $8.59, $7.92, $7.21 and $6.41.   

Earlier than you think about Voyager Therapeutics, you may wish to hear this.

MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Voyager Therapeutics wasn’t on the record.

Whereas Voyager Therapeutics at present has a “Reasonable Purchase” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The 5 Shares Right here

MarketBeat’s analysts have simply launched their high 5 quick performs for January 2024. Study which shares have probably the most quick curiosity and commerce them. Click on the hyperlink under to see which corporations made the record.

Get This Free Report